How Public-Private Partnerships Are Shaping Global Cell & Gene Therapy
In advanced therapies, progress rarely happens in isolation. Cell and gene therapy (CGT) depends on infrastructure, collaboration, and regulatory certainty - all of which are too complex, costly, and strategically vital for any single actor to build alone. That is where public-private partnerships (PPPs) step in: alignment engines that share risk, accelerate translation, and anchor long-term manufacturing and data capacity. When structured and executed well, PPPs become more than funding mechanisms - they define the shape of the industry that follows. They create the training pipelines, supply networks, and translational ecosystems that turn one-off breakthroughs into reproducible therapies.
Why PPPs Matter in CGT
Every new therapy requires more than an idea: it needs clean rooms, viral vectors, automation systems, analytics, registries, and people trained to operate them. PPPs are how that invisible infrastructure gets built. Governments de-risk capital investment. Academia and hospitals supply translational expertise. Industry brings scalability, digitalization, and commercial discipline. When these forces align, they generate a multiplier effect - regional capability, investor confidence, and faster access for patients.
Introducing the VantagePoint™ CGT Public-Private Partnership Tracker
To map this alignment, Lonrú has compiled and analysed 16 major PPPs announced between 2019 and 2025, covering North America, Europe, Asia-Pacific, the Middle East, and Latin America.
These include high-profile initiatives such as:
AMP Bespoke Gene Therapy Consortium - USA (Rare Disease Program)
Tailored Genes - Canada FedDev (Viral Vector Expansion)
ARC Hub - Ireland ERDF (All-Island Therapeutics Initiative)
OmniaBio - Canada ISED (Commercial CGT Facility)
Berlin Center for Gene and Cell Therapies - Germany (Integrated R&D Hub)
GEMMABio & Fiocruz - Brazil (Gene Therapy Manufacturing Partnership)
Together, they represent more than USD 1 billion in disclosed investment dedicated to building CGT infrastructure, automation capability, and workforce readiness.
What the Tracker Shows
Global momentum
Since 2023, PPP activity has accelerated sharply. Governments from Ireland to Saudi Arabia have launched multi-year programs to localize CGT capacity, shifting emphasis from research to manufacturing resilience.
Manufacturing dominance
Nearly every partnership includes a manufacturing or supply-chain component - from vector production (Canada, Germany) to AI-driven process automation (OmniaBio) and GMP workforce programs (UK BEIS / CGT Catapult). For enabling-technology vendors, this signals sustained demand for automation, analytics, and digital QC solutions.
Regional diversification
Europe and North America still lead, but Asia-Pacific and the Middle East are expanding fast.
Singapore’s A*STAR-SCG Cell Therapy collaboration and Saudi Arabia’s KFSHRC facility underline how new manufacturing corridors are forming outside the traditional biotech capitals.
Vendor-signal patterns
Across all records, Manufacturing / Supply Chain appear in more than 80 percent of cases; Analytics in 60 percent; and Workforce Development in 20 percent. The pattern is clear: global capacity building now extends beyond facilities to skills and data - a direct opportunity zone for Lonrú’s enabling-technology clients.
Inside the Tool
The new VantagePoint™ CGT Public-Private Partnership Tracker brings this dataset to life through an interactive interface built on Google Cloud Run and powered by Lonrú’s analytical framework.
Key features
Global map and timeline - Plot PPPs by geography, investment value, and modality; explore temporal trends from 2019 to 2025.
Filter controls - Slice the data by continent, region, modality, vendor signal, or investment range.
Sortable table view - View, search, and export partnership details (partners, objectives, investment, and verified source links).
Dynamic charts - Visualize investment flows by region and vendor-signal category with interactive tooltips.
AI Insight Generator - Powered by Gemini through Google AI Studio, this feature analyzes whichever view the user is exploring (filtered or global) and generates 2-3 concise, evidence-based insights.
With no filters applied, it produces a global overview.
When filters are active, it delivers context-specific intelligence (for example, “APAC manufacturing momentum” or “RWE infrastructure gaps in Europe”).
Each insight is classified under a VantagePoint™ Lens - INSIGHTS, CONNECT, ACCELERATE, VALIDATION, SCALE, or ILLUMINATE - mirroring Lonrú’s consulting framework.
These features transform the tracker from a static register into a dynamic intelligence environment - a living map of where collaboration and capital are building the next phase of CGT.
Explore the Data
The full dataset and interactive tool are embedded below.
Use the filters to focus on your region or vendor category, then review the AI-generated insight cards to see what the data implies for your business.
VantagePoint™ CGT Public-Private Partnership Tracker
A VantagePoint™ INSIGHTS Product
The CGT Public-Private Partnership Tracker sits within Lonrú’s VantagePoint™ INSIGHTS suite - tools that convert regulatory and market complexity into actionable commercial foresight.
By illuminating the partnerships building tomorrow’s therapy infrastructure, it helps enabling-technology companies see where capacity, collaboration, and opportunity will converge next.
